TUCC physicians are known throughout the country for their highly specialized skills. Here are a few links to PDF files and video clips of recent news stories that featured TUCC physicians, patients and our center.
Dr. Jesse Mills of the Center for Men’s Health at The Urology Center of Colorado explains commons misconceptions about erectile dysfunction (ED). By separating the medical facts about ED from common disbeliefs, Dr. Mills offers hope with multiple methods of modern treatment that bring relief from this widespread condition.
This weekend, college basketball takes center stage, while a few fans are using any excuse they can to catch all the action.
Doctors in Denver are seeing a direct correlation between March Madness and when men schedule vasectomies. It seems, for this surgical procedure -- timing is everything.
"Most of the time these guys are looking for excuses to tell their wives about why they have to stay inside and watch basketball on TV," said Dr. Jesse Mills, director of the Center for Men's Health at the Urology Center of Colorado. "Here's a great carrot for them. Here's a great incentive."
Heat Biologics, Inc. (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today the first patient has been dosed in its Phase 1/2 bladder cancer clinical study with product candidate, HS-410. HS-410 is an investigational biologic designed to activate a T-cell mediated pan-antigen immune response for the treatment of bladder cancer. Dosing for the HS-410 Phase 1/2 study was initiated by clinical investigator Lawrence Karsh, M.D., F.A.C.S., at The Urology Center of Colorado in Denver.
"We are very pleased to begin dosing bladder cancer patients with HS-410. This represents a significant milestone for our Phase 1/2 study and an exciting step forward for Heat's clinical development program," said Jeff Wolf, Chief Executive Officer of Heat.
Most are apprehensive about the thought of seeing an urologist. Many are even more nervous upon arrival at the doctor’s office. The Urology Center of Colorado (TUCC) has successfully combined expertise with peace and calm. TUCC is the most comprehensive urology center in the Rocky Mountain Region and boasts the most well-trained and experienced doctors, including those performing robotic surgery.
The building itself was thoughtfully designed by the architectural firm Boulder Associates with an open floor plan. The center, founded by 13 doctors, was skillfully built with multiple amenities and opened in December 2006. There is natural light from the window at the end of each site line. The “Suite” concept is repeated distinguished not only by Colorado names but with matching colors and art. The Red Rocks Suite, for instance, has red signage and red-themed art. The other comfortable suites are: Browns Canyon, Turquoise Lake, Mesa Verde, Maroon Bells and Blue Mesa.
September was Prostate Cancer Awareness month, but doctors want you to be aware all year round.
The National Cancer Institute estimates there will be more than 238,000 new cases of prostate cancer this year.
Dr. Mark Jones with the Urology Center of Colorado was on 9NEWS Sunday Morning as well as cancer survivor, Kelsey Canady.
Prostate cancer is the most commonly diagnosed cancer in Colorado today. Over 1,200 Coloradans put on their blue shoes, shirts and hats to recognize these men as participants in The Blue Shoe Run for Prostate Cancer. The fourth annual Blue Shoe Run, benefiting The Urology Center of Colorado (TUCC) Foundation, is one of the top fundraisers for prostate cancer screening and research in Colorado.
Taking place just north of Sports Authority Field at Mile High, The Blue Shoe Run featured a 5K run/walk, 1.5-mile family walk and kids fun run. The winning 5K times included Gerald Romero who completed the race in just 17 minutes.
Congratulations to three TUCC physicians who were recently recognized as 5280 Magazine Top Docs: Elias Hsu, M.D., Jesse Mills, M.D., and Brett Abernathy, M.D.
There's just no substitute for patients stepping into an active role in advancing research. In this video, Dr. Larry Karsh, Director of Clinical Research at The Urology Center of Colorado, explains the important role patients play in clinical research to advance treatment options for prostate cancer.
In 2003, urologist Richard Augspurger, MD, and healthcare administrator Bob Asinof developed a plan to create a singlesite, full-service urology practice. So they began pitching their vision to individual practices in the Denver area.
“Bob and I saw where medicine was headed, and we knew that large-group practices were the future,” said Augspurger, TUCC’s medical director. “We wanted to be big enough that we could capitalize projects, because it’s very difficult to do that in a small group. We also wanted to offer the highest-quality care to our patients, and one of the best ways to do that was in a single location. Finally, we wanted to offer integrated ancillary services to our patients and capture the revenue [technical fees] that we were previously sending out.”
TUCC physicians and clinical investigators Lawrence Karsh, M.D., and Jesse Mills, M.D., presented the results of a national clinical evaluation of the treatment of Peyronie’s Disease at the American Urological Association 2013 Annual Meeting. Three phase 3 studies have been conducted to examine the safety and efficacy of collagenase clostridium histolyticum (CCH) in subjects with Peyronie’s disease (PD). The effect of CCH on change in penile curvature deformity from baseline to end of study was analyzed by the subjects’ duration of disease or degree of plaque calcification.
Treatment with CCH resulted in improvements in curvature deformity regardless of duration of disease or level of plaque calcification; although small differences were noted within the subgroups, they are not expected to be clinically meaningful.
TUCC is contracted with all major insurance companies. We look forward to providing you with clinically advanced, compassionate urologic care.